Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJPC-401 for Myocardial Iron Overload in Beta Thalassemia
NCT03381833Phase 2Terminated
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Nov 2017
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of hepcidin in iron overload, sponsored by La Jolla Pharmaceutical Company. Started Nov 2017; status: terminated.
02
Drugs
hepcidin
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT03381833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381833.